-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UX7guConJhr1jCXAPcC+Y2HU0B0G8URe6FMLsNmm7nVdioXvBjBkJiznIHCylRMS
 hmGFpaGuhf8KqNuQ7Z7FTA==

<SEC-DOCUMENT>0000950123-09-043943.txt : 20090918
<SEC-HEADER>0000950123-09-043943.hdr.sgml : 20090918
<ACCEPTANCE-DATETIME>20090917191520
ACCESSION NUMBER:		0000950123-09-043943
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090914
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090918
DATE AS OF CHANGE:		20090917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		091075415

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c90303e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): September 14, 2009</B>

<P style="font-size: 24pt" align="center"><B>CHAMPIONS BIOTECHNOLOGY,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-17263</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>52-1401755</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Science and Technology Park
at Johns Hopkins<BR>
855 N. Wolfe Street, Suite 619, Baltimore, MD<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>21205</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(410) 369-0365</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid"
nowrap><B>Inapplicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>INFORMATION TO BE INCLUDED IN THE
REPORT</B>

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;2.02.</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify"><B>Results of Operations and Financial
Condition.</B></DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt; text-indent: 4%" align="justify">On
September&nbsp;14, 2009, Champions Biotechnology, Inc. (the
&#8220;<B>Company</B>&#8221;) announced its results of operations for its
fiscal quarter ended July&nbsp;31, 2009. A copy of the Company&#8217;s press
release announcing such results dated September&nbsp;14, 2009 is attached
hereto as Exhibit&nbsp;99.1. This Form 8-K and the attached exhibit are
furnished to, but not filed with, the Securities and Exchange Commission
(&#8220;<B>SEC</B>&#8221;) and shall not be deemed to be incorporated by
reference into any of the Company&#8217;s filings with the SEC under the
Securities Act of 1933.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;9.01. Financial
Statements and Exhibits.</B>

<P style="font-size: 10pt" align="justify"><I>(c)&nbsp;Exhibits</I>

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The following exhibits are filed
herewith:</DIV>
</TD>
 </TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">Exhibit&nbsp;No. </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated September&nbsp;14, 2009</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="justify">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<P style="font-size: 10pt; margin-left: 48%" align="justify"><B>CHAMPIONS BIOTECHNOLOGY, INC.</B><BR>
(Registrant)


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top" align="left">Date: September&nbsp;17, 2009 </TD>
  <TD valign="top" align="left">By: </TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">/s/ Douglas D. Burkett</TD>
 </TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Douglas D. Burkett<BR>
President</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c90303exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">


<P style="font-size: 10pt" align="right"><U><B>Exhibit&nbsp;99.1</B></U>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="80%">&nbsp;</TD>
  <TD width="20%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top" align="left"><IMG SRC="c90303p9030301.jpg" alt="CHAMPIONS BIOTECHNOLOGY INC. LOGO"></TD>
  <TD valign="bottom" align="right"><B>NEWS</B></TD>
</TR>

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center"><B>Champions Biotechnology Reports
Fiscal 2010 First Quarter Financial Results</B>

<P style="font-size: 10pt" align="justify">Baltimore, MD September&nbsp;14,
2009&#8212;<U>Champions Biotechnology, Inc.</U> (OTC Bulletin Board: CSBR), a
company engaged in the development of advanced preclinical platforms and tumor
specific data to enhance the value of oncology drugs, today announced its
financial results for the first quarter ended July&nbsp;31, 2009. Full details
of the Company&#8217;s financial results are available in the Company&#8217;s
Form 10-Q at <U>www.championsbiotechnology.com</U>.

<P style="font-size: 10pt" align="justify">Total revenues for the first quarter
of 2010 were $962,000 as compared to $673,000 in the first quarter of 2009, an
increase of 43%. This increase was derived from the Company&#8217;s
Personalized Oncology business, which generated revenues of $899,000 for the
first quarter of 2010 compared to $616,000 in the comparable quarter of last
year. This increase consisted of increases in Personalized Oncology Tumorgraft
studies and vaccines, partially offset by a decrease in revenues from physician
panels. Preclinical eValuation revenues for three months ended July&nbsp;31,
2009, and 2008 were $63,000 and $57,000, respectively.

<P style="font-size: 10pt" align="justify">Costs of Personalized Oncology
services for the first quarter of 2010 was $634,000 as compared to $226,000 in
the first quarter of 2009, an increase of 181%. The cost of Personalized
Oncology services increased due to an increase in the number of Tumorgraft
studies, which have higher expenses (lower gross margins) than revenues derived
from our physician panels. In addition, the Company recognized the costs of a
vaccine development study which required additional up front expenses. Cost of
Preclinical eValuation services for the three months ended July&nbsp;31, 2009,
and 2008 were $34,000 and $34,000, respectively.

<P style="font-size: 10pt" align="justify">Research and Development expenses
for the first quarter of 2010 was $496,000 as compared to $231,000 in the
comparable quarter of 2009, an increase of 115%. The increase in research and
development resulted from the Company&#8217;s continued efforts to build its
Tumorgraft platform and development costs associated with securing the
Company&#8217;s future drug pipeline candidates. <BR>
General and
Administrative expenses for the first quarter of 2010 was $806,000 as compared
to $334,000 in the comparable quarter of 2009, an increase of 141%. The
increase is primarily due to the continued investment in our corporate
infrastructure to support our overall growth and expansion into Israel and the
United Kingdom.

<P style="font-size: 10pt" align="justify">For the first quarter ended
July&nbsp;31, 2009, the Company reported a net loss of $1,003,000 or ($0.03)
per share compared to a net loss of $131,000 or $0.00 per share in the
comparable quarter in 2009. <BR>
The Company&#8217;s cash and cash equivalents
on July&nbsp;31, 2009 was $1,530,000 compared to $2,745,000 at April&nbsp;30,
2009.

<P style="font-size: 10pt" align="justify">Doug Burkett, Ph.D., President of
Champions Biotechnology, Inc., commented, &#8220;this past quarter we saw
continued improvement in the Company&#8217;s revenue growth and we continued to
build our Tumorgraft platform.&#8221; In addition, the Company continued to
make progress during the quarter on the following fronts:

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR  style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"  valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"  width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">1.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The Company saw quarterly top line revenues
increase 43% year over year.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"  border="0">

 <TR  style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"  valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"  width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">2.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Promising discussions with numerous companies
for additional service contracts in the Preclinical eValuation business yielded
another large new customer early in the second quarter.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"  border="0">

 <TR  style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"  valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"  width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">3.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The Company advanced its due-diligence and
negotiations to in-license promising oncology compounds by leveraging its
Tumorgraft platform to select the most promising candidates.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"  border="0">

 <TR  style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"  valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"  width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">4.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Champions established a collaboration
agreement with Do-Coop, an Israel based biotech firm to develop a more soluble
form of its SG410 oncology drug candidate. The soluble form was developed by
Do-Coop which enables SG410 to advance to Tumorgraft testing.</DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">5.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The Company conducted its first Personalized
Oncology Panel&#8482; in Israel and built infrastructure to grow the business
there.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">6.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The Company launched its
<U>Personalizedcancertreatment.com</U> website that provides information and
access to the Company&#8217;s personalized treatment program.</DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="justify">Furthermore, as previously
announced, since the end of the July&nbsp;31, 2009 quarter, the Company entered
into a major collaboration agreement with PinnacleCare, the world&#8217;s
leading private health advisory. This partnership will enable Champions to
educate many more physicians regarding the Company&#8217;s services and assist
many more individuals with cutting edge research to personalize their cancer
treatment.

<P style="font-size: 10pt" align="justify">For more information regarding
Champions Biotechnology&#8217;s business and recent news, please visit
<U>www.championsbiotechnology.com</U>. To learn more about personalized cancer
treatment, please visit <U>www.personalizedcancertreatment.com</U>.

<P style="font-size: 10pt" align="justify"><B>About Champions Biotechnology,
Inc.</B> <BR>
Champions Biotechnology, Inc. is engaged in the development of
advanced preclinical platforms and tumor specific data to enhance and
accelerate the value of oncology drugs. The Company&#8217;s Preclinical
Platform is a novel approach based upon the implantation of primary human
tumors in immune deficient mice followed by propagation of the resulting
engraftments (Biomerk Tumorgrafts&#8482;) in a manner that preserves the
biological characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts, these Tumorgrafts closely reflect human
cancer biology and their response to drugs is predictive of clinical outcomes
in cancer patients. Champions Biotechnology leverages its preclinical platform
to evaluate drug candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the Company
plans to sell, partner or license them to pharmaceutical and/or biotechnology
companies, as appropriate. The Company also offers its predictive preclinical
platform and tumor specific data to physicians for personalized patient care
and to companies for evaluation of oncology drugs in models that integrate
prognostic testing with biomarker discovery.

<P style="font-size: 10pt"
align="justify"><U>www.championsbiotechnology.com</U>
<BR>
<U>www.personalizedcancertreatment.com</U>

<P style="font-size: 10pt" align="justify"><I>This press release contains
&#8220;forward-looking statements&#8221; (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as
&#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221;
&#8220;will,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221;
&#8220;anticipate,&#8221; &#8220;plan,&#8221; and similar expressions to
identify forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company&#8217;s actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See Champions Biotechnology&#8217;s </I><I>Form
10-K</I><I> for the fiscal year ended April&nbsp;30, 2009 for a discussion of
such risks, uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology&#8217;s future results, levels of activity, performance
or achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in
Champions Biotechnology&#8217;s expectations, except as required by law.</I>

<P style="font-size: 10pt" align="justify">For more news and information on
Champions Biotechnology, Inc., please visit www.IRGnews.com/coi/CSBR where you
can find the CEO&#8217;s video, a fact sheet on the company, investor
presentations, and more.

<P style="font-size: 10pt" align="justify">The Investor Relations Group, Inc. James Carbonara, 212-825-3210 or Public Relations: <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Susan Morgenbesser / Janet Vasquez, 212-825-3210


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c90303p9030301.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c90303p9030301.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$(`_`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"C;RL&WE8\A^,OQC\+_!7PI)XF\2/(XDD^S:=I]N
M`UUJ%V5RL,*9&!_><X"@Y)KU<GR?%9SBUA,+'7>4GI&$>[.#,<PHY;0=6IN]
M(175]C\\+S_@H]XA6\`L?AUIWV$R<)/J\@O/*)'!$4+1K)M[;L9[U^AP\,8>
MR]_,6JBZ<GNW];K9GRG^MU6[MAHJ/J_\C[6^`'[2GA/XZV=S#I\,FC>)=-B6
M?4M`NV4S);,ZQB\MG4XN+4R.J[UZ%@#UKXK/^&<9D%2/M?WF&G+EIU5M?>TN
MTM[+J?0Y7G-#,;P@O95HJ[@^VE[?-_YGTJI^48]*^<VTVL>SZ;#J`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`C8@'&/
M?TQ_G-)NVB6U@VT/RS_X*/6VI>7\/+O$HT9'U*WD*#]VE^^UX]^2%R8\>E?J
M7AG*E"KCZ:_BM1DO*/Y[^1\3Q=&?-AFOX:3797W?H['Y8$J@`C)R#N)(`((Z
M`8)X_'FOU])]K>1\4ON/MO\`8"MM2F^.[7-F&%I8^%=9EU7:!Y1MK@V<$"-S
MC_C^FMB!ZPG'0FO@/$6M1IY`J<U^]G7I^SB]'>-VVOE=>K/HN&83_M2G*"?+
M3A/F=MDTX_C?Y_,_<->%';';TS7X:MET_0_2=OD+3`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`@FF2V1I)'"(B[B20`,=AGN
M3_.G%.Z27W";4$V]$OD<Q+XA0YVX2,?=Y53^/.0?H>]="PTM/+I_2.=UM?=:
MBO5%NTN+F]"O'E(><.W`)SVYR>?>L90ITKNZN[:W_I&L)SYM$DE_7DSY[_:T
M\"VGC'X)>*8KP(]UHL"ZSILA.SRKJT=?NDN/O(S`@G!KZ+A''RP.=X5T7I7?
MLYK6W++TN>1Q!AXULNJ-I1E0]^.ZU\M3\+#X=N`N?+6/C.6,F%SCJ"N.K#\Q
MZU^_?78)VU^27^9^7)375:=-OT/L_P#9:\$^-XM%\4:_X!NI+77K'5=/COH[
M"\^SZC-IIMR\*M`[(MY9-,SR&.3Y"T*G;G!'\F?2;I\<8Z/#;X1KUZ>&PLZE
M>O"A)4Y>UC[D)-K6I%1E[U+6.EW&3M;]4\-?[*A/,99E"#J2C"%/FO[L6W-V
M2^&[BE?=[;7O]N>&?V@O%_AZY_LCXC:(S/`PCDO(;?[#?`';AWMBB12C&[YD
M"9QQGJ?YMR;QHXBR:M'!<9Y94J.#Y95?81PU6]W=\L(TZ3233?+%WMIN?I>*
MX>P=>/M,LK)*U^5RYDE;2SNY:ON]#ZF\,^+M"\660OM#U""[BP-\:GRYX">J
MS0/AHV!]1@]B:_?\@XHR?B3#QQ&58RG632<J?,E5IMJ[4HWNK=]CY7$X.O@Y
MN%:FX=G9I/T=D=."1Q_+']*^B6FE]O3]#F_`=3`0G:/IVZ=:/P7W``/'3;[9
MSC\J/38/P%H`*`"@!I('X?UI72^70-OD"YYYX'0=,9I1;U#8=T]L?AC-5MY6
M`*`"@`H`*-O(`H`/I0&WE8;G!(]/IWHV\@%!_3\*/0-O(6@`H`.G'3';IC-`
M!TX].W3K1MY`-!.<8VX]QW]J-%LPV\AWTH#;RL>8?$?7/[*M[*U!*_:92[8P
M,K&0=I'<;B.E>AEN'<IRDK)4^FVZ?W=SCQ<^11BE:_R/+K37DGO+:%G`26XA
MB8;L+MEDC3/7J`Q/X&O5G0<:<G&&L5)KRLF_Q.&+UCII?T/2?B3\0+;X<Z%#
M+!:?;-1NCY&FV0;8C,BC?-*5&1"F1G')+`5Y>79=/,J\Z?.J<*:O*35[-WLK
M*V[_``.S&XN."HQDH\TI:1BM-N_8^"?'_CWXC?$*&?3]7U`6VC3-SI-C&+>W
M*`Y"2NHWSC/]\FOT++<LR[*W&I1A>O'_`)>2U:?DME\CX[&8G&XQ2A4GR4G]
MB*:7S/%3X`/_`#SX]"H_P_S@>E>Y]>_O,\OZCV5ODSJ/"UEXE\%:BNJ>&-0N
M=)NQD.UNQ$<\9((BN(ONS1C'`8'K7'C5A\=0E0Q"YDU[K<4W"5K*4;Z7OK;9
M]3HPU.OA*BJ4)NG+;2ZNGOM^';H?7/@OQI:?%!X_"?Q&TJT76)8_^)7KUG&+
M:1YE&0K[0!',<L0%^5NF*_&>._#+(<[P524\/&IRI\LVK5:+;?O1E&S<4K+7
M7=]3[G(>(L9AZT:,Y<M33;2+M;>/1]3-U+PEXF^%OB!+K2[N18&D+6MRF5AN
M(5.[R;A!PS`$Y4]>HK^/LSR'/_#S/%7P6(=/"TY<U.M%2C":;TIR5[-]&S].
MI8G!YIAI*I#]]:W*VK)]9*R5CZC\!>.;;Q79!)$%MJELH%S`2`'``'GP^L9/
MY=Z_H?@CC&EQ+@[5X+#9A0252',GS7^U&UM&?*9A@98*K9/FIO5/M?HST7]*
M^]_`\[;Y'QY\;/VQ/`OPEU:7PK9V-WXK\5P>4MQINF2QK#837"AX8+J?8^9R
MK`F%`6`/.#Q7UF0\(8_.:"Q4I1P.%UM.HF[V[)6TUO<^?S+/\-@)^QI1=>KU
M46DH_/6[\CQSPW_P4#LDU&ULO'7PYUKP];7DZ117D'GEH5D8(':TNH%>X&6'
M^J.>>AKUJOA]B8TJM3"YEA\3[)-\L$UM>ZOS-+;J<%+BJFIQA6PDZ:;^*ZTO
MY6\^A[_\<_VF]*^"VD^#]8/AV]\0VOB\@VGE7$=@UO"T*SJ\J31D[BC#Y<`@
M]:\#(^&\1G=?%X>EB*>%G@HN4W*+DM'RV7*UUZGK9AG%++Z="HZ4JL*_PV:C
M;2^MT?06C>((]7\,:=XC2V>&+4M'M]72V9U+QI=6BW0A+@89@'"D@=:\.M0=
M#$U<,Y)NC4=-M:*ZERMVZ(]*E6C4P].O%64X*:CUU5['SW^SY^TU9?';6?%V
MCV?A>YT!O":6;22SWL5T+K[9=7]L`HCC7R]IL6)_ZZ`=J]W/.&L1D6'P.(JX
MFG7CCE)P4(RBX\L(2?-=N_QVT[7ZGG9;G%/,:E:E3H2I.@E=N2=[N2TLE;:_
MS/6?BY\2]+^$O@36_&NJQ^=%I<2?9K)9$BEOKR=PD%K&S=&8DD]>%)KR\HRV
MKFV88?`4+0==N\VKQ@DKMM(Z\PQD,OPM3$37P_#'9R?9'DO[-_[2^E?'F+Q!
M"ND'0-5T)X'-@]VEPUQ9SC`NHR%!55E^0CU->MQ)PUB.''AO:5HXBG7O:4(N
M/+)='=_,X<HS>&9>UBH>RG3L^5O=/JCU3XR_$^#X0_#[5_'=QI4NK1:3)I\;
M6$-PEL\AO[ZWL@?.=2JA#<!CQSMQWKR\GRV>;YA0R^G45"5;FM.2;2Y(2F]%
M9ZJ-OF=N88V.7X2IBI4W-4^7W4[/WI*._P`SSW]GS]I7PW\=[36DLM.FT#7-
M#N8UN=%NKF*>62PN`PMM0MI$5?,A::*>)@!E&B&X_.M>AQ!PUC.'9TU6G&O1
MJJ\:M.+C&ZU<6FW:5M=]3ERK.</F:FH1="K"S]G)IMIVNTU;177WG&?';]L/
MPM\%?$\'A%-#N?$VK):BZU-+*^AMH].65?,@AE+HVZ=H_FV\8!&>M=V0\&X[
M.\)+&0K0PE).T.>,GSVW<>5JROH<V9<04,MKK#JDZTDDY.,DE&_1WOK8[/XH
M?M#6GPT^%?A[XG2^'KG4K;7QIGEZ7%=Q036YU&,2`-.\95M@;G`&:X,GX>JY
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M(]1M/#UQX?'A_48=/>.XNX[DW!FMH[GS%:-%V`>9C!STK7B'A^OPY7H4*M>&
M)E7A[1.G&4%'WG&S4F^U[^9&59K3S.-65.C*C[)I-2:>^M]$K'#_`!F_;(\"
M_"W69O"VF:?>>+O$]N[17%CILBBVLI_X89YU5R\I/_+.,;J]#).#,QS:A]:J
MSA@<)+6$ZFKE'K))6LO4Y,QXAPV!FZ%*#KUHZ-1:2B_7K\CR?PI_P4$TK^UX
M--^(/P^UGPG;7;@1:BOG&.WC)V^;-:W,*22)@Y)0\`5Z>(\/<5"A.K@LQH8R
M5.[<()IVZ:J32?RU..CQ33YU'$865*+MK?;OI:[/MSQ#\2-&TGX<ZM\1])V:
MYH^FZ%/KUO\`8YD5;VVAB$P6*7!",P..>A!R.*^'IX.K+,:>5SBZ&)G6A1:D
MFN64Y<MVNRO=GT4\91C@IXZF_:4H4W45M+I:M>3/%/@!^U?X3^-]YJ&BIIDW
MAGQ!9H+FVTR\O(;AM0LN%:>VD15RR2[E9,$@`-T/'O<0<*8WAV%*K4J1Q-":
M]ZI3BX*$KO1IMO:SOYGG99GN'S&I.E&F\/4C\,923YE:^EDBS\<?VF;#X+>+
M_"/A2Y\+W>MS>*DBD2ZM[V*V2T6:^%B`R21L7(8[N".!BHR/AJOG>$QF+I8B
MGAH8)ZJ<9-RM'FTY6N73O<>99S3RVO2H2H2J.HKKE:CRW=NJU^1U/QJ_:"\*
M_!'P[8:SKMO<WU_JX5=)T:R=%N;N0QB5\NX(BBC4_,Y!]!R:YLER#%YUBYX;
M#M0A2;4ZDD^6/GI^1IF&;T,OH4JDXN4ZJ3C!-)V:3W^9\IZ5_P`%"+>VOHF\
M6_"_Q#HVC74BBVOXC*K>7(R@2!+FV5;DX+$")AGC'6OJY^'E1PG]4S7#UZU.
M]Z:5FK1NU=2WOUM8\:GQ2HSC[;"3A3>S3Z-[V:VMV\S]%M&UBUUK2=-UBR69
M;34[*VO[9;B-H)Q!=Q+-&)86`,4FUQE3R#7YY5I3H5:M&5N:C.4)6=U>+:=F
MMU=:,^LI5(5*=.K#X*D5):6TDKK3YG@/[0$TMBN@7:DI&TD]N6SM4.4\T`GU
M.P\5]!P]&,I8B#2O9-+KO9V^\\O-9."IM:*]KGSD/$;PM&T<FUHW1T*@95HW
M5@>/<?C7TJPJDFN5I:JSTW/'^L-6UV_0];\6:C'\08=#U&)PP@TJ".:-/F-O
M>LQ-W&X'W#E!QZ`5XN#IO+)5Z37*W4;5]/<M[K/1KM8J-*2DERQ5_+OL<D/!
MP7E82.WW#W]MM=WUU[7,/JD>CL)_PAXSGR3GK_JR/TVT?76M+VMYC^J1[BGP
M>#C,)XZ?NR,9Z]%H^NM=;?,/JD>]OP+NF^&Y-.OK.^A1HY+*ZM[J/"[?F@=6
M../[JD<=<^]95L3SPG3Z5(RBU?O_`,%F:PWL*M.I35W=7MI:VS_0^KO%.D6V
MO>&IXIHPT@MA<P-@ADE1-^01R.-U?CW%V3TLURC&X:K1]K*G&=2G[MVI1NT?
M:8'$2PU:FXRLM$[;69\Z:$EWX?U6UU*S=E,$VUX^F^$X\R(J.-I7)Y[X-?SG
MDCQ>2YGAL?0O2G"IRU(J[4HK1Q:[):[;GU%?DKTI4Y)6:T?9]'<^H=4U5K;P
M[?:Q:@NT&DW%_`HY)9+5YD7`Z9(`K^K\#46+IX.M"SA7C3DK?WXIVTZZGQ6(
MO055)>]3YM/0_)3]AGPMH_Q$^)WQ!\<^,;>#6-:TLPZE;0Z@JW)75-<O;Z>\
MU'RWR&=##Y:'!"^8P'08_8^/<57RO*<LR_`3>$P]96E*-XIJ,86BGZ:[WVN?
M!<-X:CBL9B:V(BJLZ5I13[MRN[?+T/U/\0_#[P/XH?3V\0^&-&U$Z7=0WMA)
M<V<0DM;J`[HGC=`K<'G:25Z9%?E6&S''8-U(8?%5J2JQ<9^\TFGOY:_>?:5<
M!@ZO)[7#4[0=XZ)6?RL?GO\`\%&5CATKX;)&BHD.I7OE1I\J!4MS\O'"K@8%
M?H'AHF\=F"4G:5'WFO.2_7\3Y?BM*%+"I)146[)=-#SW1OVX/B-I/AC3/#\/
MPP26SL-'M-*AN\WH,L45I';1S`BWQEE&1V^85[%?@/+JN,K8AYKRSJ5)5''W
M%9MN337,<%+B3%4</3H1PT;0@H*7O7LE9/:QO_\`!.69'\6_%V4@1&>RT";9
MG[OG:AKLA4$X)P6(Y`K#Q(I^QP.24T]*7MHW](4?\CIX2?\`M&-EM>-/3S;F
M:_[<WC,^*?'?@3X*V%[%#9M?:=J/B"7SE2*VEO9_+A%T2<(8+#S9_F(&)17-
MP'@?J67YCGDZ?O0A.%%6]Y\JU<?65D/B7$^UQF'P"GRP@XN?1)RMOZ+7YGEN
MDW6@_LX_M->&W\*:Q8WW@K7[6PTZ_;3[R.:V\O4!';SBXD1V`,-YB4!B.6KU
M*RK<3<*XEXJC*./PDYRBI1M+3WE9.V\=['GTI0RC.*?L:JG0ERIN+NK/1K3S
M/NC]M5XF_9R\8^6RLCS>'F1@P*NC:[IQ5@>A4C!S7Q'!"2XEP*MK'VJ:[?NI
MGU/$MEE-;E>\J;T_QQ/RS\*_\)Q\`M/^%7QW\,>;<Z1XKL]9L=1CDW):_:K/
M6-0M;C2+UURJQW%I:VEU"S<[X9O[I%?JN,^H<15LVR#$I0JX*5.5-K22C.G"
M7.EW4GRR\K=U?X>A]9RN.$S"B[*MSVTT]V;@XOU23_X8Y+QSX1\4ZIX)3XW^
M+;BY^V>.O%&I1V)N,JUY"J>;->J&_P"7<R-LAV?+Y:#'&*ZL!C<'0QSR#!17
ML\!AUS*/23VCIHM-7=W4F95J->5-8VM>V(J2LWU:LV^^[/OK]JD[?V2/AKP.
M!X8XZ`YM%KX#@W_DK<RT<?X^FWVCZC.%;(,#T^#;T,3PC^TC\!O#_P"S_IWA
M/6;>#6_$UIX8FL;C1/[#9FN+Z19E2+[;/`(P`75C(9!C;D&GCN&>(L3Q'+%8
M=U,+A7B%-5%-Q2AITOMY&6'S/*J&51H5:4:E=0:<>76[>FMOU.8_8X\/Z[9_
M!S]H3Q%=6US:Z)JG@O5[#3O-218;F[T_P[KK74]ON`$BI'=Q0LXSS&`>G';Q
MIB</_;G#>%C-2KT,11<[6NN>M22O;:[3=C+(J52&7YU5Y;4IX>JE?354YMV^
M_P"=S<_8=U*XT3X0?'#5K'(N]-:[OK3:,D7%KX?\Z$@#DX=%.*PX^A3GGF1T
MJC4:=2G",O\`"ZTK_@:\.5)4<!F=2"]^*=O7DT,K]@WP;H?C7Q;XZ\=>*H+?
M6-;TV\1[-;]5N##=7SM-/>^5+D&7)VAF!QCBM>/\56R[`9;EV#G.AAYPLW"\
M59+1773N9\-8:CB<7B*]>*G4IZJ,E?5O5V/L?]K+X<^$_$_P7\::G?:981:M
MX;T.^UG1]2$,-O<6MU80M/'$)U53Y,A78R$X(8U\7PKF>,P6<8.E1K5'"M4A
M"<6VU)2=GIW7EJ?0YY@,/4P%:I[.$)T8N49))/36UU;?8^3/V<_$6HZI^QY\
M;=)O999K;0(=?M]->4N1%;7NB6]W):QENBI<M(^T<#[1[BOKN)\+0PO&>2UJ
M:4)8FI1E);/G51KUNUK]YX.559RR'-:3?NT:<N7_`+>3O\M/S/C'P/X5\;>&
MO!=I\>O!UQ<(_A+QD^E:A]G20/81);VMU!<7#)Q_9UPMT]M)N&`73NPQ]OF6
M-P.(QTN'L=3A;&8?GIN=M7)RC97ZJR:MJ^VA\_AJ&)I4?[1P[E%8>IRMQ7PN
MT7=^3YK'L_QY^+6F_&/Q/\!O%EAM@NGLK*UUFP\U6DL-4@\0*L\+HOW`WWT8
M_>5ABO!X?RBODF$XAP=5.-.\G3;5E*+IZ-/TT/0S3'0QU3`UHZ3C!1FD]FI=
M?7<^KOVU?A#XT\9Z1X&\9>#=-NM=D\*VVV_TJTA:YN5AEBBE2\AM5!,R1R(-
MZJ"=I)Q@5\MP3FV!P&*Q^#QE1898NZC5E+EC>[7*V]$VGH].Q[&?X#$UL/@L
M1AH.JJ,(J48Q;:T3OITZ,\0T/]L>W$>G>%/CE\)-/O[&PEL[?[1#IJ07%D;5
MHMMV=/O(HVW1J"Y2!B3LP%).*]O%<%3_`'F+R+-YQG44GR<_Q*2NTI1;O?I=
M'G4<\CR4\/C\!3G"FTKJ/+*-M/+SZZW/UG\-:WI'B+0=)USP_<V]]HNJ6-O>
M:;=6I5H)+6>-7B,97C`4@8[8QVK\FJT*N%JU*%>,J=:E*2FI:2YKZW7J?>T:
MM.I2IU*%O92BG'EV2MMIM;L<+\:/"EQXJ\#ZG!IZAM2L%&I:>G(9YK8%V@&T
M]98]Z#CJU=^2XM8/'4IR=J-3W)=+*77Y/4YLSP[KX2<8+]Y#WHK;5=-NI^6[
M^(949U,^QH\K(GF`%70LCIC;G>&0@KU!R,#BOU=4(*UH^:W6^O?;70_/OK#6
MRVWUMK]QVG@GXIR>$M05[A1>Z7<L$OK0%3*%5S^_MW.`DJJ>A`#C@<X)X,?E
M<,52:I_NZT=8RV7I+K;\GY'7A,QEAIJZ?L_M+[]5^NU_S^Z/"E[X8\9Z;%J?
MA^]M[R!E!DCC9?/M9",F&[A'S02`\?-Q[U\'BH8O`U94L1"5.4=GTDN\7L_E
MJ?4X:>'Q$>>C45[*\=+Q]4I:?<CJ!X:C_P">)'L`N!_X]7+]:?\`-^?^1T^P
M2V>W]W_@A_PC47_/$_\`?*__`!5'UI_S?G_D'L//_P`E?^8A\-1`']R>`?X5
M[?\``J/K3_F_/_(/8>?_`)*ST:Y*VVC-NP"+3RPN,9+1[0`,GUKYK-Z\</@<
M9)^ZN245TUDFE^?S/6P\;RI+M;Y'BS:,"6;R=IP>`)``?4!1C_\`77X0LL?*
MI<K;YV[7L[/923MI_P"`OO8^C5;E272/R/8=`@WZ';6MPH*^0\+(W.8LLNTC
MTVG'TK]HX856&3X2-31P32WM9-I63O;3S?JT>#BU'V]5+12^6Y^3_BGX9?&C
M]E/XK:QX]^%&@W_BKP3JSW;_`&2RTVYU6-=-N[AKQM(UBSL-]U;&TF9EAOE#
M+Y:*6)+NA_>\+FF2<6Y30P&;XB."Q^&LDY24&WRJ/M*=[1]]I<T=;6>RU7YM
M7P689!BY8C!P=3#RVE:\;/[,DM5;H]$WUO>)U0_:<_:E^*.JZ3HWP^^%-SX9
M\N[MWOKZ;2=8OK.94<>9'>ZEJ>GV-KIUDPR'X:3CY'R,'D_U8X3RBG7K9CFZ
MQ/NR4(*4:;OLN2,93<I7VUY7>[5C:6=9SC9TZ>$PKHM.-U&+E_X$VK*+]$_,
MZ/\`;D\->-O$OAOX6>1X9U+6-6ANG;6X?#>F:KJ]O97+6R^<5^Q6DCK#YVX*
MT@7CN:XN`Z^"P>89BW7A0PSIM0=:<*;:<M%=M*]NB9T\34\0Z&#]I"];[2A=
MJ]M;'W)X/T."'X:^'(+G2HHKR/PAIT4\$UDL=TMRNE1*\4D;QB1)A)D%2`V[
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M]C>^.'[#.D>!?`UWXK^'&I>,/$6O:5-;3'2)XH+V:XM/,'G-9V^FV*SM<QC#
MA5R#CI7+D7'M;&9C#!9E1H8;#5U*+G!.$4[:)RE)V736VG4WS/AV&#PKQ&$J
M3FZ;3<96OZJUOF>B^,M8\9?$;]B>[M+[PKXH7QCI9T+0[W1I?#VLQZO=-IFL
MZ:L-W#ISV0N9XGL1%(\J1%05E)(VG'E9;0PF5<<4IPQ=%X.HZU2,U.*IP4Z=
M2R<N9J-G[NKUNFMT=.(K5<7PW+GA)5Z,J<6K.[2G#7IWZ7]3T_X%?"72_'/[
M*WA/X?\`Q$T+4;..7^U9+BQO;2XTG5M/N%\0:A<6]S#'=Q)+:S>6P92R<K(1
M@@UYN?YM6RWBW'YEEN(C=>RM*#C.G-.E"+C[KLT[)/5M=UT[LKP%+&Y%A\/B
M:<DE*HX[QE%JK/57]7TL^QYI^W1X"OO^%:_#WPYX&\*ZM?V>B:A-:6NF^'=(
MO=1%A90V,,,(>&Q@E:),(%#,HR0:]7@+'PI9EF>(QV+A3E7A=SJR46Y-M]6K
M];_+N<7$V&4,-@:6'I-0IN22BG9:+LM&_P"KDG[3?AGQ)J7[+'P\TC3/#NN:
MEJMK_P`(W]ITO3])O[W4+?RK91()[&TMWFAV$8;<@V]\57">*PM'BG,*U;$T
MZ5*2K<LYSC"+O+2SDTM>@9O3J?V%@J:A+FCR:).ZT\CM_@9^R[\(-2^&_@S6
M?%WPUMQXIFTV.XU--5.M6UPMT)7S]JTZZNU6)L!<HT*Y';FO.S_BO.(9KC,/
M@\S?U:-1JGR<CCRV2O&2B[[]_/<Z<IR3+ZF"H5:^&O6DM;RDGOUC?R[:GT[X
MV\/V.E?"KQMH7AW2H;6"/P/XHM-.TG2K,(&DDT._2&VM+2WC.^:65@H548NS
MXP2U?,8*K.IG&!Q%:LW-8JA*<ZDM$O:P<I-MJUE=WOIW1[.*HTZ.6XNC0I\D
M(X>JHQBNOLY6226[?EJSXH_8)\%ZWIW@WXEZ7XM\.ZSHT&K:Q%#]EUS2-0TI
MKJTFTJ*"X$4=];PM-$0SJ64$9R,\5]KX@8[#8G,,NJX.O"LJ5'5Q::352;L^
MGG9]&?/<+T)+#XVG5IN*F^6STT<;/\SQC6_AY\</V1_B5JWB[X::#>>+O`FJ
M22F2*TL+K4H)K.21I5M-4M-/WW-A<P%B$N55H\=0>E>Y0S'(>+LLPV#S/$1P
M&/H)).3C"TDK7AS-1:?5;H\ZKA,QR'&3K86$JE%MV?*W%Q?226WWKN,\<?&/
M]I+]IK3D^'GASX6:CX6T35'BM]:G2RU@V\T9<;TU#7=2T^SMK"Q.T[X]A=PI
M4,>A>`R3AKA:L\QQ6;PQ5:BG*A#W(M-=H1E.4Y-M<MK6WUZ&*S'-<VA'"4L+
M*G%VY^52L]=')M)1CZ_>?7MA\%#\(_V6?&O@73(Y=9U^]\,:Y?ZLVGP33R7^
MN:A91QRP6-NBM+-'&D44,:A2S"$'`+D5\;5SI9OQ3@<PJ\N'HPQ%%04Y6C"G
M"6[D]$VG)O9:]%J?0+*WE^18F@DY5ITIM\JU;<=K+?6R7??J<-^Q!X#O/^%-
M^-O#/CGPUJ5E::SXGU""YTO7]+O]*>\T^XT?386*07\$,ICX=1(H&&3*D$<>
MAQWF$)9S@L5EV)A*5*C!J5.2?*XU)O[+T?77??8Y.&*'-E^+H5Z3C"=5IQ:M
MO3AL?%WQ2_9C\8?"KXOZ1;^&_#VO^(?"%YKFG:AH^I:5I-_J2V5H-1B>2RU*
M2RMY%M98.1ND(W(`V:^TRGBO!YMDM=8FO3PV,ITI0E"4U&[Y=X\UE[W8^=Q^
M4U\!C(PC"4J4I7A)1>S>BLNI^A'[1'BO]HWPC!X4U?X0^&H=8T#3+:&Y\06D
M%G)JVJ7;K"%-G-I$02Y^Q@98O:-YNY1P!P?SOAS"<.8JKC:6<8MX:M4<E1ES
M<D(J^DE+6+E?9-V?8^IS.MFV%I826"I<U*$(\Z4&W=+526]O17\SXB^+/Q0^
M*7[16CZ?X(A_9WO=,\3KJ%K)-K=OI&KO?PS0D;H?M%YHUFNDV4S./,:ZNVC5
M5^;=@&OM<GRG*>&,0\S_`-9?;X90FE1E*"3OM[JE)MK6TK1UTZNWSV.Q^)S6
M$,-_9JIUE*+YX)\ST=TER[/>UWZWU/U-^!7@/4/AM\)_!7@S5;E)]2T31X8+
MUHFW0I=2%IIX8FR-T<<DC(#W"YK\PSS'T\QS7&XRBO9TZU1N*>CY59)M=VDK
M^9]ME6%G@L!AZ%7^)&-Y+^5R?,U\KVOU/82JX*E1@@@@@=#U&*\M:;:6VZ6/
M0MTV1^9/[5?P.U?P]=7GQ$\%:>UWHUX[S>(-,MHV,FE738WZC%%$V9+&53+Y
MBJ,I)(TGW7:OTSA//:->,<MQL^2M3THSD[*<>D+O:2TLWNDET1\'Q!D\\-*6
M,PJ_<2=YPCI[-OKT]UW>G1M]&SX%/B:<2'B$`;]JF1Q(`7.,MYG:7&?E&2#T
M/3]`^K)+X7;TTV].WX'RG.UUM;S\_P#,^A?@9IWBK6=577=)\07WA'2[.=([
MC5+.=TGO2A#/900E@DT>.#)(&3G[M?CWBAQ_D?!U*GE^)ITL5F5>#G&C.*?L
MX2NE/7KS;I6:ZL^OX6R/,,SJO$4)SH8:DU&4XMJ[W<4EOIUU1^D1\1WFHVL-
MOIU]=W=Q'&$:2+$;LR(`7GEB"KO8\G8IY/&,U_+>)XRS/.:<GA,56I5+ODAA
MYRI6=WHW2=K:J]]_O9^L4L!1PME5I*R2]Z23^=GW.,A^)/B#P)JP_P"$JAFU
M#0)V4SL`'N].4G_CYC,A)FB5L!HRW()QR`#X&`\1^(.$\PIT^(%6Q>5UVN=U
M)2G6I7E:4_>;DHQNFDO==FE:YVSR;"XZBY8.T*]/:*2C&6UEI9.^N^J\SZ7T
M^^TO4;&UU'3YDN;*[A2XMKB$;EEBE7<C`D="#_2OZ!PN>X+&8/#X_!SEB,)B
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MGD^&]K/"TL6Y5XIM)Q=NCM>RMH[GH/\`PM"PM=?\5Z=?V:6>F>&=!T[6WU'S
M/GGCU"$RI"8/+`C<<*/G.2>U?7U?$*EA<TS?"XS"I8#*\'3QBK*_/+VL8RA3
MY==?>2O;S?4X5EK]E0=)_O*U25/EM:W*[7OV.1;XN^.$L!XG;X9W'_"&C][]
ML_M6'^UQIY.?[0_LT1`>7L^;9NW8KYW_`(B1Q;"@L[?"')PW=25;F3JJD_\`
MEXHJHI*ZU_A6_,Z995@O:?5EC?\`:=N6WN\W:^OR=Q?%'QC\5:-;66LZ1X*L
MM5\*ZM-IUOH^KOK:P2W<VHE$B22T6V8PD3LT9RV`5R3BEG7B5Q/@HT,PRWAR
MEBLCQ\J,,'B9SUG4JI+V<E&O!QES\T-8Q2=GS%8;*,+.4J-7%^SQ%%2<X<K]
MU1W:T=]-?\BSK'Q,\>:%%X9MKOP%9)XB\4:MJ.G66D_VVOD^1I]I!=+-]M%L
M0K.LDWRL`!Y?4Y&;S#CWC'+*.1PQ7#5*CG&<XK$TZ6%=2T73I0P_+:2KM1<W
M4T;J)=TMS.EEN!JSQ+IXS]S0A&3ER6>KDGHH]-.GS-RT^('BK2K+5]6\>>$;
M;PQI&EV;7*7-EK":I+<S[@J6BV\<,9\QV("GID]J]C"\;\29=ALPQ_%W#M/)
MLNP=*]*I"M"K*I6;Y845&.(K.\NKLM+]C*67X6I*E2P6)]M5E*SCRN-E:[=[
M+;^MS'M?B9\09!9ZG)\,;G_A';^6)8I8-7CEUB."X8"*ZET]XE5$*L"5#Y`[
MUYF&X^XQJ4\/CZ_!SADN+DG3J4ZC=?DE*T9<GM7.VM_X21K++L"G*E#'KVU-
M:J46HI]4G;?YG<>#_&H\37/BNVET]+`^&=6.F`M.)'N1]F2X\YU*#RF^<J5!
M89'4U];PKQ=/B!\0NMAX86.48KZO"/M+.2_>+W[RY8N\+/E=F<F+P/U:.'Y9
M.2KQYKVT7I]_4\OO?CW'I>B:=KEUX?(MKOQGK'ABX2WNV=[>UTDQ[M2A!MU,
MTC+(#Y1"<*WS'`S\1C/%NM@,NR_,,5E\(X>MFN,P57EE)N-+".D^:"O\34VG
M?2ZO9]?0I9"ZM:I0I5'S4Z%.HD[)>_=_+H_._J>C:O\`$2SL]1\"VVG0V^HZ
M=XSN+J.._CN`BVL$%H+H3*JH1(6!(()7%?8YOQW0R_%\+T\&H8K"<15*G[Y/
M2G3IPC)[/XO>UNNAP4LNDZ>-<[TYX11M&V[DVOEMT.0E^*OBK5[O4O\`A!/`
M1\1Z)I%S-:S:M<ZI%8"ZGMV(G33X2A,FT@@,2.>HKY>OXB<29AB,8^%.&/[4
MRW`SJ4ZF)G-)2]F[2Y+U8-]=(QDWV.J.582E"E'&XQ8>M.*E&"C>R:NF[*VO
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MLX=1N-]ZMCIVGV5PH>&2YN-C$O(I&$4`\U[F>\>XNCF-#)N%\I>>9I4I0KOW
MN6E3ISBI^])3IJZ35[S6O<YZ&71=&5;&5EAJ,9.*5O>;3Z*S_(R+KXF>,]&T
M2[U?7/AY-IL>BW]K%K446I1W"#3IL^?J6FO%%_I*0C#/&X3CH<UQ8GCSBK`9
M=4QV9\*/"/`UJ4<5'G4E[&=W*I2:G.ZC:S]YV;1I#+<'*K&G1QJ?M(MTTHN-
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M&^UV7B2Y\-Z3I-I.);G6+R)]D"(S1@1,['+?*P4`G)KE7B9'"Y3FN/Q>!2KX
M3'3P6$PU-OFK5(M**U=T[OWFODC59.Y5J%*G4M&=)59R:TIQ>]RYHGCKQ_)K
M.DV7B3X;/I=AK$A6#4=.U2WU#^S2(3*%U.,JGE@@-ET/;`!.`3*N-.,/[2P&
M%XBX2J8#!YI)1H5*#YW!M.2]KRU:BBN7?GY-=M=":V!P,:51X;'*I*A\47'D
MOTO'17/;%(Q]T?EZ\^GO7ZQ%I75GHSQ[6T):T$036T,\4D,T:212*4DC=0R,
MK`@JR,,$$$\&DTTDHR=-Q=TUHUUT^8G%6<6DUU3V^X^#/C9^Q)X8\7W%[K_P
M^ND\*:_<,TTNG%<:)=RL&)(A3!M'+,Q)CP#N.1TK[O)>.L7EL*>&S"'UK"TU
M93?\6';7[2TZGR>9<+4:W-5P4O859._L]H6ZV[?D>.ZCX"\;?##0M"T*[TJ:
MRAA@^R;].\V[2XDA(:XN$>!#L29B2,X/.*_@SQTI<08KC?'9Q7=2KA,>T\,X
M1<5"FEI3Y5HFNLE;F>I^P<%1PF%R6A@FHTJV'O[2[7O2;?OWTW[=%H?27PK\
M4+IUC$9].O`2FTA[.=#E5SSNC[^M;<!YS/+*"G7RZK%027\.5G]^KOKZ?,,U
MP\:U1J%9;]U\]M/0Y?XQZR^J6MX(=.O&,B&)?*L[AL>9D#!6(Y`R"?I7D^(.
M8U,TE*=#"5>6I\7[MKDB]DOGLK;)M[HZ,IIQPW+%5HJ4+-7:U::;OV5NOW':
M?LUZEK*Z/8Z1J#7C6S?VT8;:[C>-M/33[FS,7E"10Z0RKJ#*%/`^S';WK[7P
M9S#'491RJM.K4PF(I8ENG43Y:+PWU54_9_RJI[:?,M+N-UU/.X@5+VE2I!)2
MNKR6SYN9O[FOQML?62VJ+G"^^.F#_2OZ)AAHQA&*6D?3KJ?,^TDDE\-MA?LZ
MKS@8';`JO8QI^\XJT0YWML9'B6.5_#^LQ0H7D?2[U(T4$LSM;2!%51U);`P.
MN:\GB2%2MD&<4:4%*=3!5U&/G*G)6T]?F:X1J.)HR>BC.+_%7/@"S\/Z?+X,
MTO3+?P[X^;QQ;0VK0(RWBZ)'JD,Z,CM!(_DK:JRH3\N.,@5_),<DP?\`8-'"
MQR[-UGD9).GRS6&53VE1KW6O=7*WKW5D?:SKS6,G5=:@L-R[JRGR\J6G6]W^
M+/7[_P`&^(O$FL?$&QN+=X-0U'P5X9BCG\O;:3:G9Q>;+;K)C:_SKM(']ZOO
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MR-%5GA\11G7G1Y'>+]E9./.OB:1W>D_%V]:UTS18O`WB%O$:?9[.[LFLFBL[
M<QA8YIS>$!/)`!8$=J^NP/B+C%A<KR^'#.*J9I>%&M3<'3I0Y;1NFUHGOY'+
M5RJ*E5JO%TU1=Y1DI:Z]+(Y?PO\`"VS\3>(_B'JFOC7M.E;Q&XLDL]0NM/BF
MMY+.%VD"PLHG`E4KN]J^9X9X#IY[CN*<5FBQN!G''S<:5.;IQM*5:=[:<[5T
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MNG;N[^AT/A3Q7??"BQO_``=K_A?6[F6VU"_GT>^TNR>[MM3@NIGEBW/&/W4N
M7"G=7O<.9]C.`:&8\.9ADF)Q-6EB:]7#5*4&Z=9UI.4=4M$V];G-B\/#,94L
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MSB[&\59-'AO`</XFAF>-=.%=SBU3H):-IV5KW=GTM9[E8;!4\!B/K4\3"5*B
MVX6:;EVT\]RK<:/?_#+7]4GO=-U74_#7B/0=.TRZU+1DDFO],N;&V6%CB,[X
MU8@E67H:XZN6YAP5FF/HXC`XG&Y/G>#C3JXG#1DZV&GRQOR2UM9W3\MC6-2C
MCJ4'"I"GB,/-RC&>D97=]MC5^$6C75SJ_BR?[/XD_P"$0O;"WL["+Q1+-+/=
M2L3]H=8[AF81E,#D5Z7AOE-6IF&>N5+&RX?Q%)0A'&W<IR=^96EIJNNZ,LVK
M15'"J+IQQ5-R;=-62V:V_IF3X`31_A+I7C_Q3JFE7D$=KXRFT#3F,3-='1/M
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MN7UWPK\1)O$-UI#1>4VI)'M%V;8-]_*L[)CAB`*^?R[A_B.7#SS6>%E4S'(<
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MR/3HMJ.[6C&^`8X_[5UN38GF+]F0/M7>J$.2@;&0N><9Q77P10HPGBI0HPA)
M5*R34(IVYJ>ETKVV,,;)^ZKNW+'2_G(]8']3_.OT==?5GG[>5A&^Z:FI\#0(
M:X&SIV%*27LY*VG*_P`AK1Z:6^179%4#"JOT4#U]!44Z=-2D_9Q3Y8W?*KZ7
M\A2;2W:^8J@9'`Z^@ITXQ52HU%)WWMJ-Z6Z6'[$#[MB@XZ[0#^>*AT:2J.:I
M04[?%RI2^^UQW=DKZ=A'4;2,#''!`]1VHG&+552BFE%NS2>MM]>HEI:VEOD!
M5>A48`&`0.,@=JFI"$J<5**DE&-DTGWVOZ#^';W?P&(BJ&VJJ\]@!WXZ"JC3
MA"*Y(1A:71)?D2F^X\H@R0B@^H4`_GBFZ5)2YO904N_*D_OM<:;2M>PP@`':
M`.>P`['THC&,:BY8J+<I7LDK^Z]Q/2/:R^XD55"C"J,'(X`P<\GVJXTZ:4;4
MXKEE)KW4K-MMM::.^MQW?<`!O;@<'CCI]/2M)1C9/E5UMIMZ"6C=M`D1,G*K
MP!C*CCZ<<5SU:<'.+E"+:VNEIZ7*BVMG;\`*K@<#CIP.,BJY(MJ,HIJZT:36
MSZ!=J]G;_AQ-J@#"@<]@!W]J:IP@XN,(Q=VKI)::Z:=`3??8%1%Y"*IYY"@'
M\\5C[*G3]^%.,)RO>2BE)Z]6DFQW>U].PQ`-Q!`QSP0,44DG*I&2NK+1ZK[F
M3\+5O=]-"9551A0%'H`!_*NB$8P2C"*A%=$DE]RT!W^X\\\>VUO<:9ID-Q;P
MSPGQ'IA:*>))(R1.[*2CJ5)!`(XZBOC>-J%">78.$Z,)0^OX:3C*$6N9-M2:
M:M>^J>]SOP,I1KU'&3B_8S6CMHTK['>(J_*-HPNS:,#"\#&!VK["E"'LJ2Y5
M:,8\JLM-%LNGR.!:.?0F*JI&%"\]@!5QC&#ERQ4;ZNRM]]A/2W2WX"[0#@`#
MIP`!VJ5&,>91BHI]$D@($15DP%51M8D``=^X`]_UJ(4J=*K)4Z<::DFVHQ4;
GNZWLE??KW*DW=:[$Q`4X4!0.@`P!]`.E-QC%M12BET2LMNR)/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
